Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Trial Details

NCT ID

NCT06282445

Phase

PHASE2

Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Adebrelimab
• Oxaliplatin
• Capecitabine
• Bevacizumab

Locations (sample)

• Jinhua, Zhejiang, China|29.10678,119.64421

Key Eligibility Criteria

• The patients voluntarily participated in the study, signed the informed consent, and had good compliance.
• 2\. Age 18-75 years (including 18 and 75) .
• 3\. Metastatic colorectal cancer confirmed histologically and/or cytologically and initially unresectable.
• MSS or pMMR.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.